Loading company…
Swiss biopharmaceutical company focused on commercializing therapies for rare diseases, founded in 2014.
Founded in 2014 and headquartered in Switzerland, Swixx Biopharma SA commercializes innovative therapies for rare diseases and aims to improve patient access to treatment. In May 2024 it agreed to fully acquire Pharma Consulting Group S.A. Swixx is a portfolio company of HBM Partners and Merieux Equity Partners. Its stage is Series B.
Funding rounds, investors and people for this company come from licensed data. A free account shows the first rows of each section; an approved contribution opens every profile in full.
Sign in